Patisiran (ALN-TTR02)

Jul 04, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Background: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. Methods: In this phase 3…
Read more
Alnylam Rare Disease
Alnylam® Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi)…
Read more
alnylam_logo.png
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: Oct 09, 2023 - FDA Cites Insufficient Evidence of Clinical Meaningfulness - - No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
Read more
alnylam_logo.png
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR Amyloidosis
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…
Read more
Subscribe to